- Home
- MYPS vs IMA Comparison
MYPS vs IMA Comparison
Compare MYPS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYPS | IMA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | 543 | 15 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 54.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MYPS | IMA |
|---|---|---|
| Price | $0.42 | $5.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $16.00 |
| AVG Volume (30 Days) | 350.5K | ★ 382.0K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $3.94 |
| 52 Week High | $1.68 | $17.50 |
Technical Indicators
Market Signals| Indicator | MYPS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 55.38 |
| Support Level | $0.42 | $5.69 |
| Resistance Level | $0.49 | $7.04 |
| Average True Range (ATR) | 0.03 | 0.47 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 12.30 | 62.50 |
Price Performance
Historical ComparisonAbout MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.